Syndax focuses on developing entinostat, an oral drug candidate that enhances the body's immune response to tumors. They are currently evaluating entinostat in clinical trials for lung cancer, melanoma, and breast cancer. Additionally, Syndax is developing axatilimab, a monoclonal antibody for chronic Graft versus Host Disease, and SNDX-5613, an inhibitor for acute leukemias. The company was founded in 2005 and is based in Waltham, Massachusetts.